Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10059)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
TGFB1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
In Vitro Model |
PLC/PRF/5 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0485 |
| Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
| Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
| SNU-387 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0250 | |
| SNU-449 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0454 | |
| SNU475 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0497 | |
| SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
| HuH-6 cells | Hepatoblastoma | Homo sapiens | CVCL_4381 | |
| Response regulation | TGF-B1 represses xCT (SLC7A11) expression via Smad3 activation and enhances lipid peroxidation in hepatocellular carcinoma cells with an early TGF-B1 signature, which would benefit from the targeting of GPX4. | |||
Hepatocellular carcinoma [ICD-11: 2C12]
| In total 1 item(s) under this disease | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
| Target Regulator | Transforming growth factor beta-1 proprotein (TGFB1) | Protein coding | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
In Vitro Model |
PLC/PRF/5 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0485 |
| Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
| Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
| SNU-387 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0250 | |
| SNU-449 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0454 | |
| SNU475 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0497 | |
| SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
| HuH-6 cells | Hepatoblastoma | Homo sapiens | CVCL_4381 | |
| Response regulation | TGF-B1 represses xCT (SLC7A11) expression via Smad3 activation and enhances lipid peroxidation in hepatocellular carcinoma cells with an early TGF-B1 signature, which would benefit from the targeting of GPX4. | |||
